Santhera Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:SPHDF) $13.35 0.00 (0.00%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$13.35▼$13.3550-Day Range$0.68▼$13.3552-Week Range$9.40▼$13.35VolumeN/AAverage Volume3,788 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest About Santhera Pharmaceuticals Stock (OTCMKTS:SPHDF)Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.Read More SPHDF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPHDF Stock News HeadlinesOctober 27, 2023 | finance.yahoo.comSanthera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophyOctober 26, 2023 | reuters.comUS FDA approves Santhera's Duschenne drugNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comOctober 13, 2023 | markets.businessinsider.comSanthera: Europe's CHMP Issues Positive Opinion For AGAMREE To Treat Duchenne Muscular DystrophyOctober 13, 2023 | markets.businessinsider.comPositive European Approval Outlook for Santhera’s AGAMREE Bolsters Buy Rating: Potential Milestone for DMD TreatmentOctober 13, 2023 | finance.yahoo.comSanthera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular DystrophySeptember 8, 2023 | seekingalpha.comSanthera Pharmaceuticals reports 1H resultsSeptember 8, 2023 | finance.yahoo.comSanthera Pharmaceuticals Holding AG (VTX:SANN) Is About To Turn The CornerNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comSeptember 7, 2023 | finance.yahoo.comSanthera Announces Half-Year 2023 Financial Results and Provides Corporate UpdateJuly 31, 2023 | benzinga.comSanthera Completes Divestment of Raxone®/Idebenone Business to Chiesi GroupJuly 31, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Santhera Pharmaceuticals Holding (SPHDD)June 29, 2023 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera Publishes Timeline of the Reverse Share SplitJune 29, 2023 | finance.yahoo.comSanthera Publishes Timeline of the Reverse Share SplitJune 27, 2023 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Shareholders Approve all Board Proposals at Today's Annual General MeetingJune 27, 2023 | finance.yahoo.comShareholders Approve all Board Proposals at Today’s Annual General MeetingJune 21, 2023 | msn.comCatalyst (CPRX) to Gain DMD Drug Licensing Rights From SantheraJune 20, 2023 | finance.yahoo.comCatalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera PharmaceuticalsJune 20, 2023 | markets.businessinsider.comSanthera Grants North America License For Vamorolone To Catalyst PharmaJune 20, 2023 | finance.yahoo.comSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus RoyaltiesJune 6, 2023 | finance.yahoo.comSanthera Publishes Agenda for its Annual General MeetingJune 2, 2023 | seekingalpha.comSanthera Pharmaceuticals GAAP EPS of -CHF1.17June 1, 2023 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera Publishes Annual Report 2022May 31, 2023 | finance.yahoo.comSanthera Publishes Annual Report 2022May 24, 2023 | thestreet.comSanthera -- A Duchenne Drug With Positive Study Results That Few Know AboutMay 13, 2023 | thestreet.comSanthera Drug Wins European Approval for Rare Blindness DiseaseApril 27, 2023 | finance.yahoo.comSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate UpdateSee More Headlines Receive SPHDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santhera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SPHDF CUSIPN/A CIKN/A Webwww.santhera.com Phone(161) 906-8950FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Thomas Meier Ph.D. (Age 61)Founder & Chairman Comp: $94.62kMr. Dario Eklund (Age 55)Chief Executive Officer Comp: $920.58kMr. Andrew P. Smith CGMA (Age 60)FCMA, Chief Financial Officer Mr. Oliver Strub (Age 60)Executive VP, General Counsel & Secretary Mr. Günther Metz Ph.D. (Age 65)Head of Business Development & Executive VP Mr. Shabir Hasham M.D.Chief Medical OfficerMs. Stephanie Brown B.Sc. (Age 62)M.B.A., President of North America Mr. Marc SchraderHead of Technical Development & OperationsMs. Eva KaliasHead of Investor Relations & CommunicationsMr. Neville Kodkani M.D.Head of Global Marketing & Partner ManagementMore ExecutivesKey Competitors3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFAgentixOTCMKTS:AGTXView All Competitors SPHDF Stock Analysis - Frequently Asked Questions How have SPHDF shares performed in 2023? Santhera Pharmaceuticals' stock was trading at $14.10 on January 1st, 2023. Since then, SPHDF shares have decreased by 5.3% and is now trading at $13.35. View the best growth stocks for 2023 here. Are investors shorting Santhera Pharmaceuticals? Santhera Pharmaceuticals saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 136,400 shares, an increase of 69.0% from the October 15th total of 80,700 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 104.9 days. View Santhera Pharmaceuticals' Short Interest. When did Santhera Pharmaceuticals' stock split? Santhera Pharmaceuticals shares reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Santhera Pharmaceuticals? Shares of SPHDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:SPHDF) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santhera Pharmaceuticals Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.